Showing results (61-70 of 611) with videos related to
Sort By:
Pageof 62
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine|August 27, 2021
Rare Cause of Syncope in an Athlete, Matter of Brain and Heart ElectricityDalya Navot-Mintzer, Dana Ekstein, Eyal Nof, et al.The American Journal of Cardiology|May 27, 2006
Mechanism of diastolic mitral regurgitation in candidates for cardiac resynchronization therapyEyal Nof, Michael Glikson, David Bar-Lev, et al.Current Pharmaceutical Design|September 2, 2014
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia?Giuseppe Boriani, Cinzia Valzania, Mauro Biffi, et al.Vaccines|January 7, 2021
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBaseMilo Gatti, Emanuel Raschi, Ugo Moretti, et al.Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 19, 2014
BLOCK HF: how far does it extend indications for cardiac resynchronization therapy?Giuseppe Boriani, Matteo Ziacchi, Igor Diemberger, et al.Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|September 28, 2013
Left ventricular lead stabilization to retain cardiac resynchronization therapy at long term: when is it advisable?Mauro Biffi, Matteo Bertini, Matteo Ziacchi, et al.Indian Heart Journal|March 31, 2015
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICDAlessandro Corzani, Matteo Ziacchi, Mauro Biffi, et al.Pacing and Clinical Electrophysiology : PACE|April 12, 2003
Comparison of the cardiopulmonary response to exercise in recipients of dual sensor DDDR pacemakers Versus a Healthy control groupEric Page, Pascal Defaye, Jean-Luc Bonnet, et al.European Journal of Preventive Cardiology|August 17, 2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting systemMilo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, et al.Expert Opinion on Pharmacotherapy|November 3, 2020
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?Emanuel Raschi, Gian Paolo Fadini, Igor Diemberger, et al.Pageof 62